Pics 4: WBC/BMF/MPN/CML Flashcards

1
Q

Neutrophil life cycle and inherited neutrophil disorders

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Neutrophilia causes: acute and chronic

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

hereditary and acquired causes of HLH

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Diagnostic criteria HLH

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Neutropenia inherited and acquired

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

GATA2 vs SAMD9 associated findings

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Inherited BMF chapter table 1

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Inherited BMF chapter table 2

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

HES and CEL treatment

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

ICC hypereosinophilia classification

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Fusion driven eosinophilic neoplasms

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Approach to eosinophilia pt

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Eosinophilia definitions
Hypreosinophilia, primary, secondary, HES

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Secondary causes eosinophilia

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Eosinophilia summary

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Drugs causing agranulocytosis

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Leukocytosis differential

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Mgmt neutropenia

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Congenital neutropenia and genes

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Neutropenia diagnostic algorithm

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Mechanisms of neutrophil function/dysfunction

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Leukocytosis summary slide

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

HLH diagnostic criteria

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

HLH pathophys, multifactorial

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Optimized HLH inflammatory index [OHI]

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

H score for HLH
components

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Jak inhibitors in HLH

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Therapy for HLH principles and based on etiology

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

HLH therapy

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Treatment of hyper inflammatory syndrome after IEC

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Post IEC hyperinflammatory syndrome, pathophys

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

HLH take home points

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Ddx pancytopenia

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Inherited vs Acquired bone marrow failures

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

History clues to acquired vs inherited BMF

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Initial eval of BMF patient

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Acquired AA criteria
nonsecure
severe
very severe

A
17
Q

Treatment severe AA <40yo

A
18
Q

AA vs hypocellular MDS clues

A
18
Q

iBMF disorders quick testing guide

A
19
Q

iBMF table, inheritance extrahematopoietic manifestations [EHM] and malignancy risk

A
19
Q

Complement inhibitors chart
5 types

A
20
Q

Causes secondary erythrocytosis

A
21
Q

WHO criteria for PV

A
22
Q

Mgmt ET

A
22
Q

Management PV

A
22
Q

Diagnostic workup of erythrocytosis

A
22
Q

WHO dx ET

A
22
Q

Approach to thrombocytosis

A
22
Q

Mgmt MF

A
23
Q

WHO dx CNL

A
23
Q

WHO dx PMF

A
23
Q

Mutations in MPNs
which disorders
other common mutations?

A
23
Q

Distinguishing features of classical MPNs

A
23
Q

PV survival by risk factors

A
23
Q

IPSET for ET

A
23
Q

Mgmt PV

A
24
Q

Secondary causes of erythrocytosis

A
25
Q

Mgmt ET

A
26
Q

Ddx MF

A
27
Q

Mgmt MF

A
28
Q

Myeloid/lymphoid neoplasms associated with eosinophilia by TKGF
Which respond to TKI

A
29
Q

Systemic mastocytosis diagnosis and classification table

A
29
Q

ICC ET and post ET MF

A
29
Q

Hypereosinophilias table, classification and mgmt

A
29
Q

ICC PV and post-PV MF

A
29
Q

ICC MPNs categories, My/ly-N-E-TKGF, Mastocytosis

A
30
Q

ICC PMF diagnosis
prefibrotic and overt

A
31
Q

ICC CNL

A
32
Q

ICC MPN-U

A
32
Q

ICC CEL-NOS

A
33
Q

ICC iHES

A
33
Q

ICC my/ly neoplasms with eos and TKGFs

A
34
Q

WHO5 hypereosinophilia algorithm

A
34
Q

ICC SM diagnosis

A
34
Q

ICC SM-AMN

A
35
Q

WHO5 features of ET vs prefibrotic MF on BMBx

A
36
Q

Types of testing in CML [3]
Advantages of each, when to use, what sample?

A
37
Q

Frontline trials for CML-CP
Drug name, dose, trial name and comparator arm

A
37
Q

Criteria for AP CML

A

NOTE
WHO5 has removed CML-AP
focuses more on the higher risk features of CML, including ACAs
CML-BP is >20% myeloblasts, extramedullary disease or increased lymphoblasts in blood or BM

38
Q

CML-CP 2nd+ lines of therapy, options

A
39
Q

Cutoff for MMR, MR4, MR4.5 and MR5

Optimal response at 3,6,12 months

A
40
Q

TKI side effects

A
41
Q

Discontinuation of TKI, trials

A

General guidelines:
- Rx>3y
- >2y in MR4+
- adult
- able to monitor transcript #closely

41
Q

Resistance to TKIs, which one to choose next?

A
42
Q

Accelerated and blast phase features
- per ICC
- other features of AP

A

Other AP features:
- baso>19%
- plt<100
- WBC or spleen not responding to TKI
- clonal evolution

43
Q

Response definitions in CML

A
44
Q

Targets by colour in CML
3 months, 6 months, 12 months

A
45
Q

Targets table in front line CML
3,6,12 months

A
46
Q

Trials for frontline 2nd gen TKIs
Dasatinib
Nilotinib
Bosutinib

A
47
Q

Accelerated phase treatment: which TKIs
Special dosing?

A
48
Q

Criteria for TKI discontinuation
ELN 2020
NCCN 2022

A